Scope, claims, and US patent landscape for US 10,076,526 (dexamethasone bioerodible PLGA implant)

US 10,076,526 is directed to a dexamethasone-loaded, bioerodible implant in which (i) dexamethasone is milled to a sub-20 μm particle size distribution, (ii) dexamethasone comprises a high loading by weight, (iii) the biodegradable matrix uses a defined blend of PLGA ester-end and PLGA acid-end copolymers with a fixed 50/50 lactic:glycolic ratio, and (iv) the implant is manufactured using polymer milling plus a double extrusion process and is defined by an in vitro release target (about 60% in 14 days). Claim 1 is the core combination claim; claims 2, 3-6, and 7-8 add particle-size, ocular-region, and ocular-condition limitations that materially narrow coverage.

What is the invention scope of US 10,076,526?

Core protected subject matter (Claim 1): A bioerodible ocular implant comprising:

Drug: dexamethasone particles dispersed in a biodegradable polymer matrix.
Particle size distribution: at least 75% (Claim 1) and at least 99% (Claim 2) of dexamethasone particles have diameter <20 μm.
Polymer composition:
- Matrix includes PLGA ester end copolymer + PLGA acid end copolymer.
- Each PLGA has lactic:glycolic monomer ratio fixed at 50/50 by weight (for both the ester-end and acid-end copolymers).
Polymer-to-drug loading:
- Dexamethasone is 60% by weight of the implant (Claim 1).
- The PLGA ester + PLGA acid end copolymers together are 40% by weight (Claim 6).
Manufacturing process:
- Implant prepared by milling the biodegradable polymer and applying double extrusion to both the dexamethasone and biodegradable polymer.
Release profile:
- Implant releases about 60% of dexamethasone in 14 days in vitro (Claim 1).
Ocular context: Claim 1 is framed as “for treating an ocular condition” and subsequent dependent claims specify ocular regions and conditions.

Practical interpretation: The claims do not cover generic “dexamethasone + PLGA implant” broadly. They pin down a specific formulation architecture (high drug loading + defined PLGA end-group blend + fixed 50/50 lactic:glycolic), a drug-particle spec (sub-20 μm with specific cumulative percent), a process spec (double extrusion after polymer milling), and a release performance spec (about 60% in 14 days in vitro). A product must read on all required limitations to infringe Claim 1.

How strong is the claim set: broadest independent claim vs narrower dependent claims?

Claim 1 (independent) is both narrow and operationally provable. It is narrow because it fixes quantitative specs (60% drug; 40% total PLGA; 75% <20 μm; about 60% release at 14 days; PLGA end-group blend; 50/50 lactic:glycolic). It is operationally provable because each constraint can be tested by standard methods (particle sizing distribution, polymer composition/ratio, loading by weight, and in vitro release).

Claim-by-claim narrowing map

Claim	Additional limitation beyond Claim 1	Coverage impact
1	Baseline formulation: dexamethasone particles in PLGA (ester-end + acid-end, each 50/50 lactic:glycolic), dexamethasone 60 wt%, PLGA 40 wt%, ≥75% particles <20 μm, prepared by milling polymer + double extrusion, releases ~60% in 14 days in vitro	Establishes the protected formulation-process-performance “core”
2	≥99% dexamethasone particles <20 μm	Very tight particle specification; narrows further to ultra-narrow PSD
3	Implant sized for ocular implantation	Adds size tailored for ocular use; can matter for devices that are not ocular-sized despite similar chemistry
4	Ocular region list, including vitreous cavity, retina, macula, anterior/posterior chamber regions, suprachoroidal space, etc.	Introduces product-use specificity; could limit to devices intended for those locations
5	Ocular region is vitreous cavity	Further narrows to intravitreal use
6	Ester-end + acid-end PLGA together are 40 wt% of implant	Confirms loading structure (Claim 1 already states 60/40; Claim 6 is redundant but reinforces “40% PLGA blend” if Claim 1 were attacked as ambiguous
7	Ocular condition list: uveitis, macular edema, macular degeneration, retinal detachment, ocular tumors, infections, PVR, diabetic retinopathy, VKH syndrome, histoplasmosis, uveal diffusion, vascular occlusion	Restricts to listed conditions; depending on interpretation, may function as explicit intended use
8	Conditions narrowed to: uveitis, macular edema, vascular occlusive conditions, PVR, other retinopathies	Narrows further; potentially relevant in litigation for design-around via non-listed disease targets

What formulation variables are protected under US 10,076,526?

1) Dexamethasone particle size distribution and milling sensitivity

Claim 1 threshold: at least 75% of dexamethasone particles have diameter <20 μm.
Claim 2 threshold: at least 99% under 20 μm.

Landscape implication: Any product with dexamethasone PSD shifting above 20 μm for a material fraction risks avoiding the claims. A designer-around strategy would be to target a PSD distribution that violates the cumulative “% <20 μm” limits, while keeping other attributes potentially similar. Because the claims use “at least X%,” a small deviation around the cutoff can be outcome-determinative.

2) Drug loading: 60 wt% dexamethasone

Claim 1 explicitly recites dexamethasone as 60% by weight of the implant. This is a high loading for a bioerodible polymer system and is likely central to release kinetics and matrix morphology. Substituting materially different drug loading can break literal infringement.

3) PLGA end-group blend: ester end copolymer + acid end copolymer

The polymer must contain:

PLGA ester end copolymer
PLGA acid end copolymer

and the lactic:glycolic ratio is 50/50 for both.

Landscape implication: Many PLGA systems use a single PLGA grade or vary lactic:glycolic ratio. Claim 1 requires the specific end-group pairing plus fixed monomer ratio. Using only ester-end PLGA or only acid-end PLGA is not enough.

4) Manufacturing process: milling polymer + double extrusion

The implant is “prepared by milling the biodegradable polymer and subjecting the dexamethasone and the biodegradable polymer to a double extrusion process.”

Landscape implication: Process limitations can be difficult to assess without manufacturing records, but in litigation they also provide a potential evidentiary hook: if the accused manufacturer documents extrusion-based manufacturing with the “double extrusion” step and uses polymer milling, infringement arguments gain support.

5) Release performance: ~60% in 14 days in vitro

The implant releases “about 60% of the dexamethasone in 14 days in vitro.”

Landscape implication: This is a functional limitation that can be measured. It may also be central to validity arguments if the functional performance could be achieved by a range of compositions. Still, the claim is not purely functional: it is anchored to the specific composition and process constraints.

Which ocular regions and conditions are explicitly covered?

Ocular implantation regions (Claim 4)

The claim enumerates:

anterior chamber, posterior chamber
vitreous cavity
choroid, suprachoroidal space
conjunctiva, subconjunctival space
episcleral space
intracorneal space, epicorneal space
sclera
pars plana
surgically-induced avascular regions
macula and retina

Claim 5 narrows to the vitreous cavity.

Ocular condition scope (Claims 7-8)

Claim 7 includes:

uveitis
macular edema
macular degeneration
retinal detachment
ocular tumors
fungal or viral infections
multifocal choroiditis
diabetic retinopathy
PVR
sympathetic ophthalmia
VKH syndrome
histoplasmosis
uveal diffusion
vascular occlusion

Claim 8 narrows to:

uveitis
macular edema
vascular occlusive conditions
PVR
other retinopathies

Landscape implication: These are not broad “ocular use” concepts only. If an accused product is positioned for a condition not in the list, the argument about whether the claim covers it can turn on claim construction of the condition limitations and whether they function as intended use limitations tied to the structure.

How does the claim language drive infringement and validity analysis?

Infringement: all limitations must be met

To infringe Claim 1, an accused implant must satisfy simultaneously:

Dexamethasone dispersed in PLGA matrix with ester-end + acid-end copolymers
Each PLGA has 50/50 lactic:glycolic
Dexamethasone 60 wt%
PSD: ≥75% <20 μm
Prepared by polymer milling + “double extrusion” with dexamethasone and polymer
In vitro release: ~60% in 14 days

If any one element is absent (different loading, different PSD distribution, different PLGA composition, different manufacturing process, different release performance), literal infringement is unlikely.

Validity: likely pressure points

Even without full specification text, the constraint set suggests the likely validity pressure points in this type of patent:

Anticipation risk where prior art already discloses dexamethasone in PLGA implants with similar PSD control and loading plus extruded manufacturing and matching release.
Obviousness risk where prior art teaches general dexamethasone-PLGA ocular implants and it would be routine to combine teachings to arrive at the specific loading, end-group blend, and PSD threshold.
Enablement/definiteness pressure on the “about 60% in 14 days in vitro” functional language and the “double extrusion” process definition, depending on how clearly those are anchored in the specification.

What US patent landscape does this claim set suggest for dexamethasone PLGA implants?

Expected cluster around four claim themes:

Drug particle engineering for PLGA-matrix implants (PSD constraints, milling methods).
PLGA grade selection (acid-end vs ester-end, lactic:glycolic ratio, copolymer end-group chemistry).
Manufacturing process claims (extrusion variants, double extrusion, molding vs extrusion, milling steps).
Release kinetics targets (14-day and multi-week release profiles tied to in vitro testing conditions).

Business implication: US 10,076,526 is likely part of a broader estate where other patents may claim:

different drug loadings with similar release targets
alternative PSD thresholds
different ocular sizes or shapes
different ocular indications as method-of-use or product-by-use claims
alternative PLGA compositions (changing lactic:glycolic ratio or end-group chemistry)
manufacturing process steps (extrusion, solvent-free mixing, sterilization and stability)

Because Claim 1 combines formulation + process + performance, the patent’s practical “lock” can be harder to avoid by simply changing one variable such as PLGA grade without also re-optimizing particle milling and release.

What generic or biosimilar entry risks exist for implants protected by this patent?

This is not a conventional “bioequivalent” small-molecule exclusivity scenario; it is a device-like implant formulation patent. “Generic” entry risk manifests as design-around or full invalidity/litigation avoidance rather than FDA approval pathway exclusivity.

Risk channels:

Literal infringement risk if the competitor’s product replicates the same high drug loading, PSD distribution, PLGA end-group blend, and extruded manufacturing and meets similar release profile.
Doctrine-of-equivalents risk if the competitor slightly changes thresholds (for example, uses just-barely different PSD distribution or slightly different release profile) while preserving the same overall formulation-process-result combination.

Key design-around levers implied by the claim constraints

Claim limitation	Highest-leverage design-around lever
≥75% dexamethasone particles <20 μm	Use different milling or particle processing to shift the PSD distribution above the 20 μm cumulative thresholds
dexamethasone at 60 wt%	Change formulation loading; lower or higher drug content while re-tuning release
PLGA ester + PLGA acid end copolymers required	Use only one end-group type or use different end-group chemistry so the required blend is missing
50/50 lactic:glycolic ratio	Use a different lactic:glycolic ratio for one or both PLGA components
double extrusion after polymer milling	Use alternative mixing and shaping routes that do not include the claimed “double extrusion” step
~60% release in 14 days in vitro	Re-engineer matrix porosity/crosslinking/PSD to change release kinetics so the 14-day target is not met

What specific litigation posture does the claim structure enable?

A claim set like this typically supports:

Markman-level claim construction battles on: “bioerodible implant,” “double extrusion,” “prepared by,” and the precision of particle size and release percent.
Evidence-driven infringement anchored to PSD testing and in vitro release results. Because the claims tie to measurable thresholds, parties often focus on test methods, conditioning, and statistical handling of “about” and cumulative PSD.

Key Takeaways

US 10,076,526 protects a tightly defined dexamethasone PLGA bioerodible ocular implant combining: 60 wt% dexamethasone, ≥75% <20 μm PSD (and ≥99% <20 μm in Claim 2), a 50/50 lactic:glycolic PLGA ester-end + PLGA acid-end end copolymer blend at 40 wt% total, polymer milling plus double extrusion, and an in vitro release target of ~60% in 14 days.
Dependent claims narrow scope by ocular region (vitreous cavity in Claim 5) and ocular conditions (uveitis, macular edema, PVR, etc.).
The claim language signals that avoidance is most feasible by changing one of the hard numerical anchors: PSD cumulative percent, drug loading, PLGA end-group blend and monomer ratio, manufacturing steps, or 14-day release kinetics.
The estate is likely part of a larger formulation-process-release patent cluster targeting particle engineering, PLGA grade selection, and extrusion manufacturing for controlled dexamethasone release in ocular tissues.

FAQs

1) What do the particle size thresholds (75% <20 μm vs 99% <20 μm) change for infringement risk?
They create two distinct coverage bands: Claim 1 requires a moderate cumulative fine fraction, while Claim 2 requires an ultra-fine distribution. A product failing the ≥75% threshold may avoid Claim 1; a product failing the ≥99% threshold could still fall within Claim 1.

2) How decisive is “double extrusion” for noninfringement?
If an accused implant is made without the claimed two-stage extrusion concept and instead uses different mixing and shaping steps, the “prepared by” limitation can be a strong infringement counterpoint, especially where manufacturing records exist.

3) Does changing PLGA end groups (acid-only or ester-only) avoid the patent?
Claim 1 requires both PLGA ester-end and PLGA acid-end copolymers in the matrix, with both fixed at 50/50 lactic:glycolic. Removing either component or altering the monomer ratio breaks literal coverage.

4) If a competitor matches the composition but achieves a different 14-day release, is it protected?
Claim 1 includes the release performance limitation (“about 60% in 14 days in vitro”). A meaningful deviation from that target can be a noninfringement argument if it prevents meeting the claimed release percentage.

5) Are ocular condition lists treated as intended use or structural limitations?
They are claim limitations tied to “treating an ocular condition” with specified disease categories. Claim construction will govern whether the limitation is satisfied by labeling/indication versus only by a structure that inherently treats those conditions.

References

United States Patent No. 10,076,526.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1581193	⤷ Start Trial	C300552	Netherlands	⤷ Start Trial
European Patent Office	1581193	⤷ Start Trial	122012000081	Germany	⤷ Start Trial
European Patent Office	1581193	⤷ Start Trial	SPC/GB12/047	United Kingdom	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,076,526

Summary for Patent: 10,076,526